PD‐1‐induced proliferating T cells exhibit a distinct transcriptional signature

Strazza, Marianne; Bukhari, Shoiab; Tocheva, Anna S.; Mor, Adam

doi:10.1111/imm.13388

Cited by 8 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This notion was further supported by studies in which it was observed that following PD-1 ligation, the transcriptional signature of proliferating CD4 + T cells was enrichment in genes associated with an activated state. Furthermore, they observed that the genes induced after PD-1 ligation significantly differed between PD-L1 and PD-L2 stimulation [155,156]. These observations are consistent with the idea that PD-1 may be involved in regulating specific cellular functions beyond its inhibitory role.…”

Section: Is It Possible That Pd-1/pd-l1/2 Has Also Another Important ...supporting

confidence: 65%

Exploring the Role of PD-1 in the Autoimmune Response: Insights into Its Implication in Systemic Lupus Erythematosus

Sagrero-Fabela,

Chávez-Mireles,

Salazar-Camarena

et al. 2024

Preprint

View full text Add to dashboard Cite

Despite advances in our knowledge of systemic lupus erythematosus (SLE) has increased over time, there are still many challenges in deciphering the precise mechanisms involved in the development and progression of the disease. Recent evidence has raised questions about the effectiveness of the programmed cell death protein 1 (PD-1) in suppressing autoreactive CD4+ T cells during the autoimmune response. Research has ventured into investigate the potential impact of PD-1 on various CD4+ T cell subpopulations, including T follicular helper (Tfh) cells, circulating Tfh (cTfh) cells, and T peripheral helper (Tph) cells, all of which exhibit substantial PD-1 expression and have been closely related with several autoimmune disorders including SLE. This review aims to highlight the complex role of PD-1 in autoimmunity and emphasizes the imperative for further research to elucidate its functions during autoreactive T-cell response. Additionally, we address the potential of PD-1 or its ligands as a possible therapeutic target in SLE.

show abstract

Section: Is It Possible That Pd-1/pd-l1/2 Has Also Another Important ...supporting

confidence: 65%

Exploring the Role of PD-1 in the Autoimmune Response: Insights into Its Implication in Systemic Lupus Erythematosus

Sagrero-Fabela,

Chávez-Mireles,

Salazar-Camarena

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Ranking PD-L1 PD-L2 PD-L1 PD-L2 PD-L1 PD-L2 (Strazza et al, 2021). With our currently ongoing research, we have demonstrated PD-1's ability to differently affect cell proliferation, maturation, and diverse transcript signatures generated by the same PD-1 in different subsets of cells.…”

Section: Naive CM Emmentioning

confidence: 92%

PD-1-stimulated T cell subsets are transcriptionally and functionally distinct

et al. 2021

Self Cite

View full text Add to dashboard Cite

Summary Despite the obvious inhibitory outcome of PD-1 signaling, an additional series of functions are activated. We have observed that T cells stimulated through the T cell receptor (TCR) and PD-1 primarily do not proliferate; however, there is a population of cells that proliferates more than through TCR stimulation alone. In this study, we performed flow cytometry and RNA sequencing on individual populations of T cells and discovered that unlike naive T cells, which were inhibited following PD-1 ligation, T cells that proliferated more following PD-1 ligation were associated with effector and central memory phenotypes. We showed that these populations had different gene expression profiles following PD-1 ligation with PD-L1 compared to PD-L2. The presence of transcriptionally and functionally distinct T cell populations responsive to PD-1 ligation provides new insights into the biology of PD-1 and suggest the use of T cell subset-specific approaches to improve the clinical outcome of PD-1 blockade.

show abstract

Advances in biology, diagnosis and treatment of DLBCL

Shi,

Xu,

Shen

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL), with approximately 150,000 new cases worldwide each year, represent nearly 30% of all cases of non-Hodgkin lymphoma (NHL) and are phenotypically and genetically heterogeneous. A gene-expression profile (GEP) has identified at least three major subtypes of DLBCL, each of which has distinct clinical, biological, and genetic features: activated B-cell (ABC)-like DLBCL, germinal-center B-cell (GCB)-like DLBCL, and unclassified. Different origins are associated with different responses to chemotherapy and targeted agents. Despite DLBCL being a highly heterogeneous disease, more than 60% of patients with DLBCL can be cured after using rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to inhibit the growth of cancer cells while targeting the CD20 receptor. In recent decades, the improvement of diagnostic levels has led to a refinement classification of DLBCL and the development of new therapeutic approaches. The objective of this review was to summarize the latest studies examining genetic lesions and therapies for DLBCL.

show abstract

PD‐1‐induced proliferating T cells exhibit a distinct transcriptional signature

Cited by 8 publications

References 56 publications

Exploring the Role of PD-1 in the Autoimmune Response: Insights into Its Implication in Systemic Lupus Erythematosus

Exploring the Role of PD-1 in the Autoimmune Response: Insights into Its Implication in Systemic Lupus Erythematosus

PD-1-stimulated T cell subsets are transcriptionally and functionally distinct

Advances in biology, diagnosis and treatment of DLBCL

Contact Info

Product

Resources

About